Gradient Capital Advisors, LLC Gilead Sciences, Inc. Transaction History

Gradient Capital Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 16, 2019	SELL	$61.87 - $69.38 $205,099 - $229,994	-3,315 Closed	0 $0
Q1 2019 Apr 16, 2019	SELL	$62.53 - $70.05 $48,335 - $54,148	-773 Reduced 18.91%	3,315 $216,000
Q4 2018 Jan 30, 2019	SELL	$60.54 - $79.0 $33,175 - $43,292	-548 Reduced 11.82%	4,088 $256,000
Q3 2018 Nov 06, 2018	BUY	$71.28 - $78.92 $2,352 - $2,604	33 Added 0.72%	4,636 $358,000
Q2 2018 Jul 26, 2018	BUY	$64.88 - $75.68 $28,936 - $33,753	446 Added 10.73%	4,603 $326,000
Q1 2018 Apr 20, 2018	BUY	$72.84 - $88.8 $72 - $88	1 Added 0.02%	4,157 $313,000
Q4 2017 Feb 12, 2018	BUY	$71.15 - $83.52 $295,699 - $347,109	4,156	4,156 $298,000

1,926

992M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Gradient Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Gradient Capital Advisors, LLC with notifications on news.